Full-Time

Sr. Manager

Competitive Intelligence

Posted on 9/3/2025

Collegium Pharmaceutical

Collegium Pharmaceutical

501-1,000 employees

Specialty biopharmaceuticals developing extended-release pain medications

Compensation Overview

$174k - $194k/yr

Canton, MA, USA

Hybrid

Hybrid role requires 3 on-site days per week.

Category
Biology & Biotech (2)
,
Requirements
  • Bachelor's degree in Business, Marketing, Life Sciences, or a related field
  • 6 – 8+ years of progressive experience in competitive intelligence, commercial strategy, strategic insights, or related roles in pharmaceuticals, life sciences or healthcare consulting
  • Proven ability to lead competitive or market intelligence strategies that inform high-stakes decisions
  • Strong understanding of product lifecycles, market shaping, and global dynamics — with ability to quickly learn regulatory and drug development environments
  • Demonstrated success in translating data into strategic recommendations, engaging executive stakeholders, and influencing without authority
  • Experience managing CI vendors or external partners with an emphasis on quality, timeliness, and alignment to strategic goals
  • Proficiency with Microsoft Office (Excel in particular, in addition to Outlook, PowerPoint, and Word)
Responsibilities
  • Monitor and analyze competitor on-market products, pipelines, clinical trial data, regulatory strategies, commercial activities, and market trends to provide insights into competitive threats and opportunities in the Pain Care, ADHD and other emerging therapeutic markets of focus
  • Deliver competitive insights and provide context and objective analysis of competitive information to inform product development, launch strategies, and lifecycle management across Collegium’s current and future portfolio
  • Lead core competitive intelligence initiatives, congress coverage, workshops, monitoring/news
  • Provide scientific conference coverage and analysis of clinical data, commercial presence, key themes from a disease area perspective
  • Create and update content on competitor products, launch timelines and product profiles
  • Represent the Competitive Intelligence function in key global Commercial planning forums, providing strategic foresight that supports market assessments, forecasts, and brand planning
  • Evaluate the reliability of competitive intelligence research findings, upholding stringent standards for accuracy, relevance, and quality in all deliverables, and effectively communicate the level of evidence to stakeholders
  • Act as a strategic partner to Commercial and Business Development leaders to proactively shape positioning, differentiation, and launch readiness through competitive intelligence insights
  • Lead strategic vendor partnerships, ensuring delivery of high-impact insights while managing quality, timelines, and commercial alignment
  • Following pre-defined standards to ensure legal and ethical approaches to CI, protecting business interests and confidentiality
  • Continuously improve CI frameworks and methodologies, leveraging AI, digital tools and automation to ensure efficiency and accuracy in intelligence delivery
  • Effectively communicate key competitive information and potential implications to cross-functional teams and leadership throughout the organization
Desired Qualifications
  • Advanced degree (MBA, MS, PhD) in a relevant field
  • Experience with commercial strategy in life sciences, biotech, or adjacent industries
  • Familiarity with healthcare systems, regulatory strategy, or go-to-market models in complex environments
  • Familiarity with AI-driven CI platforms, digital dashboards, and foresight tools
  • Strategic leadership experience in matrixed, global environments
Collegium Pharmaceutical

Collegium Pharmaceutical

View

Preparing summary...

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cumberland, Maryland

Founded

2002

Simplify Jobs

Simplify's Take

What believers are saying

  • Jornay PM Q1 2026 revenue hit $38.9 million, up 36% year-over-year.
  • AZSTARYS acquisition closes Q2 2026, projecting $50 million H2 2026 revenue.
  • 30,000 Jornay prescribers drive $190-200 million full-year 2026 guidance.

What critics are saying

  • Nucynta ER loses all revenue to generics mid-2026, slashing pain sales.
  • Adhansia XR erodes 20% of Jornay 2026 revenue via afternoon coverage.
  • Vyvanse caps Jornay growth at $150 million with 40% market dominance.

What makes Collegium Pharmaceutical unique

  • Jornay PM offers evening-dosed methylphenidate for ADHD morning symptom control.
  • AZSTARYS combines serdexmethylphenidate prodrug with dexmethylphenidate for dual-release.
  • Portfolio features tamper-resistant extended-release for pain and ADHD.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-9%

1 year growth

-12%

2 year growth

-7%
Yahoo Finance
Mar 26th, 2026
Collegium Pharmaceutical shares drop 26.8% as Q4 guidance disappoints despite $205.4M revenue

Collegium Pharmaceutical reported Q4 revenues of $205.4 million, up 12.9% year-on-year, meeting analysts' expectations. However, the quarter delivered mixed results, with full-year revenue guidance beating expectations but earnings per share significantly missing estimates. The branded pharmaceuticals sector faces tailwinds from precision medicine advancements and AI adoption in drug development, but confronts challenges including regulatory scrutiny, pricing pressures and patent cliffs forcing competition from generics. CEO Vikram Karnani highlighted progress on strategic priorities, including growth for Jornay PM and maximising the pain portfolio. However, Collegium delivered the weakest full-year guidance amongst its peers. Shares have fallen 26.8% since the earnings report and currently trade at $33.51. The 10 branded pharmaceuticals stocks tracked reported mixed Q4 results, with revenues missing consensus estimates by 1.6% on average.

Yahoo Finance
Mar 25th, 2026
Collegium Pharmaceutical executive sells 50,000 shares worth $2M under pre-set plan

Scott Dreyer, Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical, sold 49,976 shares of common stock in open-market transactions on 3 March 2026, worth $2 million, according to an SEC Form 4 filing. The sale was executed under a Rule 10b5-1 trading plan established in September 2025, which allows executives to sell shares at predetermined times to avoid trading on inside information. The transaction represents 41% of Dreyer's direct holdings, substantially larger than his historical median sale of 15,387 shares. Following the transaction, Dreyer retains 71,770 shares held directly, valued at approximately $2.4 million. Collegium Pharmaceutical develops specialty pain management products including Xtampza ER and Nucynta ER/IR, with a market capitalisation of $1.1 billion.

Collegium Pharmaceutical
Mar 20th, 2026
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory – Collegium Pharmaceutical Inc.

The Investor Relations website contains information about Collegium Pharmaceutical Inc.'s business for stockholders, potential investors, and financial analysts.

AllSci
Mar 19th, 2026
Collegium acquires ADHD drug Azstarys from Corium Therapeutics for USD 650m plus milestones.

Collegium acquires ADHD drug Azstarys from Corium Therapeutics for USD 650m plus milestones. March 19, 2026 Collegium Pharmaceutical, based in Stoughton, Massachusetts, announced a definitive agreement to acquire Azstarys from Corium Therapeutics Holdings for USD 650 million in cash at closing, with up to USD 135 million in additional milestone payments tied to commercial and regulatory targets. The Collegium Azstarys acquisition covers a marketed central nervous system stimulant indicated for attention deficit hyperactivity disorder in patients aged six and older. Corium Therapeutics, a privately held company headquartered in Cambridge, Massachusetts, markets and distributes the product through its subsidiaries. The transaction is expected to close in Q2 2026, subject to Hart-Scott-Rodino approval and other customary conditions (source). Azstarys is a fixed-dose combination capsule containing serdexmethylphenidate and dexmethylphenidate, representing a differentiated ADHD treatment combining both immediate-release and long-acting components. Serdexmethylphenidate is a prodrug of dexmethylphenidate. The dexmethylphenidate component provides the immediate-release onset, while the prodrug undergoes enzymatic conversion to deliver extended exposure. Both components act on dopamine and norepinephrine reuptake in the central nervous system. The product generated more than 760,000 prescriptions in 2025 and is expected to produce over USD 50 million in second-half 2026 pro forma net revenue. Six Orange Book-listed patents support the product, most of which do not expire until December 2037. Collegium will fund the upfront payment through existing cash on hand and USD 300 million from a delayed draw term loan that is part of a syndicated credit facility announced in December 2025. The term loan carries interest at the term Secured Overnight Financing Rate plus a spread of 2.75% to 3.75%, depending on the company's first lien net leverage ratio. At closing, the rate will be SOFR plus 3.25%. Collegium expects post-close net leverage of approximately two times estimated 2026 combined adjusted EBITDA. The company stated the transaction is expected to be immediately accretive to adjusted EBITDA. Annual run-rate synergies are projected to exceed USD 50 million within twelve months of closing. The Collegium ADHD portfolio already includes Jornay PM, a delayed-release and extended-release methylphenidate capsule designed for evening dosing. Adding Azstarys gives Collegium a second commercialized ADHD product with a different release profile and dosing schedule. Collegium has historically operated in responsible pain management and has been expanding into neuropsychiatry. The Azstarys Corium deal extends the patent-protected revenue horizon of the combined ADHD portfolio to 2037. The ADHD stimulant market includes multiple methylphenidate and amphetamine-based products across immediate-release, extended-release, and prodrug formulations. Competitors targeting the same pharmacological class include: - Vyvanse (lisdexamfetamine) - Takeda - approved, amphetamine prodrug - Concerta (methylphenidate ER) - Janssen - approved, osmotic-release formulation - Adhansia XR (methylphenidate ER) - Adamas Pharmaceuticals - approved, multilayer extended-release Your email address will not be published. Required fields are marked *

Endpoints News
Mar 19th, 2026
Collegium is acquiring Corium's approved ADHD drug for $650M.

Collegium is acquiring Corium's approved ADHD drug for $650M. Biotech correspondent. Collegium Pharmaceutical is beefing up its portfolio in ADHD with the acquisition of Corium's FDA-approved drug Azstarys. The $650 million upfront deal carries up to... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

INACTIVE